Navigation Links
Slowing Down The Progression Of Alzheimer’s Disease

Alzheimer's disease is a progressive, neurodegenerative and ultimately fatal disease// that slowly destroys the brain. At an advanced stage, Alzheimer's disease sufferers lose the ability to take care of themselves and require help in every aspect of their everyday living.

Based on findings of a recent study researchers say that a mixture of peptides derived from colostrum could help slow the progression of Alzheimer's disease by reducing the build-up of beta amyloid, a toxic protein that accumulates in the brains of Alzheimer's sufferers.

ReGen Therapeutics, a UK firm first gained the rights to the polypeptide product Colostrinin in the late 1980s and initially sought to develop the compound as a pharmaceutical but over the last two years has changed its focus to the nutraceutical market and is now in discussions with partners to market Colostrinin for the 'maintenance of healthy mental function'.

In a double-blind, placebo-controlled trial on 106 people with mild to moderate Alzheimer’s disease, published last year it was found that after 15 weeks of taking the product in tablet form, around 40 per cent of the patients were stabilized or had an improved overall response in tests on cognitive function. The greatest effects were seen during the earlier stages of the disease and no serious adverse events were observed during the trial.

Latest research published, reveals a possible mechanism for this effect. Colostrinin appears to prevent the aggregation of beta-amyloid peptide Abeta (1-40) in vitro, dissolving the dense fibres that form in the brain over time. Researchers believe that this data provides the molecular basis for explaining the beneficial effect of Colostrinin in patients with mild and moderate Alzheimer's disease. Researchers at ReGen say that their company intends to begin safety studies within the next few months.


'"/>




Page: 1

Related medicine news :

1. Slowing Down The Progression Of Tumour Cells With Omega-6 Fatty Acids
2. Slowing Cartilage Loss In Arthritis With Fruit Extracts
3. NHS Food Slowing Patient Recovery
4. New Drugs Shows Promise in Slowing the Progression of Prostate Cancer
5. Progression of Glaucoma could be controlled with early detection
6. Shyness Linked To HIV Progression
7. Delaying The Progression Of Alzheimer’s Disease
8. Stopping The Progression Of Parkinsons Disease
9. Contact Lenses Found To Slow Progression Of Myopia in Kids
10. Arithmetic Skills Found To Diminish With Progression Of Alzheimer’s Disease
11. Slowing Down The Progression Of Tumour Cells With Omega-6 Fatty Acids
Post Your Comments:
(Date:12/5/2009)WASHINGTON, Dec. 5 ,, What: Cuts for a Cause ,, Why: To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2
...daq: XTNT ) today reported financial results for ...7., The company reported a net loss and net loss ...on, or $0.52 per share, for the fourth quarter,of ...mpany,s net loss per share attributable to common ...
... same results, analysis shows , , TUESDAY,...cular advantage to any single treatment for acute ...ion that carries with it a high risk of death, Can...or another, according to a report in the Feb. 20 ...
... way to spot hearing problems, study finds, , ...s may not just be a window to the soul, they may a...r senses. , A new study reports that the eyes can ... young children and in people who can,t actively t...
...tive isotopes for peacetime uses at Oak Ridge Nati...al Historic Chemical Landmark by the American Chem...enn., on March 6. , Bruce E. Bursten, Ph.D., pre...s, which began in 1946, demonstrated the peaceful ...
... Hospital, WALLA WALLA, Wash., Feb. 19 Secretary...today the Department of,Veterans Affairs (VA) will...on facility focused on mental health at the Walla ...ortance of mental,health as an issue for our veter...
...ered physical or sexual abuse as children spend up...ts, according to a long-term study of more than 3,...these women used health services at significantly ...quences from abuse that occurred decades ago, said...
Other Medicine News:Health News:XTENT Announces 2007 Financial Results 2Health News:XTENT Announces 2007 Financial Results 3Health News:XTENT Announces 2007 Financial Results 4Health News:XTENT Announces 2007 Financial Results 5Health News:XTENT Announces 2007 Financial Results 6Health News:No Difference Found in Treatments for Acute Kidney Failure 2Health News:No Difference Found in Treatments for Acute Kidney Failure 3Health News:Eyes a Window to Hearing Loss? 2Health News:Eyes a Window to Hearing Loss? 3Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 2Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 3Health News:Women who suffered child abuse spend more on health care 2Health News:Women who suffered child abuse spend more on health care 3
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 1AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 2Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 1Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 2Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 3Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 4Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 5Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 6Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 7Child Food Allergies on the Rise in U S 61410 1Child Food Allergies on the Rise in U S 61410 2Child Food Allergies on the Rise in U S 61410 3
...nificant Reduction in Relapse Rate , , - Secondar... of Patients Relapse-Free and Disability Progressi...e Tablets Planned for mid-2009 , , SEATTLE and GE...KGaA, announced today detailed results of the two-... III trial using Cladribine Tablets (Merck Serono,...
...y and safety for extended release and immediate re...ril 29 /PRNewswire/ -- New findings from two dou...ty and tolerability of pramipexole dihydrochloride...ation, for the treatment of Parkinson,s disease (P...emy of Neurology (AAN) 61st Annual Meeting in Seat...
Other Medicine Technology:Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 2Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 3Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 4Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 5Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 6Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 7New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 2New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 3New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 4New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 5
Full Body Girdle V-1655
Body Suit w/Bra above knee, Front Closure
Compression Vest V-640
Male Compression Vest Binder
Medicine Products: